Skip to main content

Genelux Corporation

corporate_fare Company Profile

Genelux Corporation

GNLX·NASDAQ·Life Sciences·CIK 0001231457

Genelux is a late clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for patients with aggressive and/or difficult-to-treat tumor types. The company's clinical and preclinical product candidates are designed to selectively kill tumor cells and trigger a strong immune response against a patient's tumor. These oncolytic immunotherapy product candidates are "off-the-shelf" personalized immunotherapies, meaning the same virus product is administered to different patients, but the resulting cellular immune response is expected to be specific to each patient's unique tumor. Genelux's lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, modified strain of the vaccinia virus (VACV). Using its proprietary selection technology and discovery and development platform (CHOICE), Genelux has built a library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. These candidates have potential use in various tumor types, both as a single therapy and in combination with other treatments, and can be administered through regional (e.g., intraperitoneal), local, and systemic (e.g., intravenous) delivery routes. The company is currently executing a late-stage clinical program for Olvi-Vec to demonstrate its ability to resensitize tumors to platinum-based therapies in multiple indications. Olvi-Vec is being evaluated in three clinical trials: a Phase 3 registrational trial in the U.S. for patients with platinum-resistant/refractory ovarian cancer (PRROC), a Phase 2 clinical trial in the U.S. for patients with recurrent non-small cell lung cancer (NSCLC), and a Phase 1b/2 clinical trial in China for patients with recurrent small cell lung cancer (SCLC). The Phase 3 registrational trial, named OnPrime/GOG-3076, is specifically evaluating intraperitoneal administration of Olvi-Vec for PRROC patients.

Genelux Corporation (NASDAQ:GNLX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for GNLX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for GNLX spans 10-Q, DEF 14A, 424B5, 8-K.

Recent high-impact activity:

  • Q3 Loss Widens to $10.29M, Missing Consensus by $1.5M as Phase 3 Costs Climb
  • Genelux Q3 Loss Widens to $10.3M; Going Concern Reaffirmed, Runway Into Q1 2027
  • Olvi-Vec Case Report Shows 16.7-Month PFS in Platinum-Relapsed SCLC
  • Genelux Q2 Loss Widens to $9.5M; Phase 3 Ovarian Cancer Data Due 2H26
  • Genelux Q2 Loss Widens to $9.5M; Cash Runway Into Q1 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$8K
Net Income
-$32.15M
Diluted EPS
-$0.86
Op. Cash Flow
-$25.27M
Free Cash Flow
-$26.37M
Operating Income
-$33.21M
Cash & Equivalents
$5.33M
Debt / Equity
0.00×
Net Margin
-4018.13×
Shares Outstanding
38.14M sh
Source: 10-K · filed 2026-03-19 · accession 0001493152-26-011616

Short Interest & Short Volume

8.32 days to cover

FINRA reported short interest of 4,530,210 shares in GNLX as of the October 30, 2026 settlement, a 2.4% decrease from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 58.7% of GNLX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,530,210 shares as of October 30, 2026
Change vs prior period▼ 2.4%
Days to cover8.32 at avg daily volume of 544,594
Daily short volume (FINRA facilities)58.7% of 169,921 shares on November 20, 2026
5-day average short volume52.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with G →
$2.2 +1.38% today
52-week range · as of 2026-11-16 $1.77 – $5.89
Market cap
$104.3M
Volume
316.4K (0.8× avg)
3-mo avg 397.4K
Live data · 2026-11-22 00:20 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GNLX - Latest Insights

GNLX
Nov 16, 2026, 4:23 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.88
Real-time Price: $2.20 info
Change: +$0.320 (+17%) info
Market Cap: $104.299M info
GNLX
Nov 16, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.88
Real-time Price: $2.20 info
Change: +$0.320 (+17%) info
Market Cap: $104.299M info
GNLX
Sep 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $2.20 info
Change: -$0.320 (-13%) info
Market Cap: $104.299M info
GNLX
Aug 13, 2026, 4:20 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $2.20 info
Change: -$0.430 (-16%) info
Market Cap: $104.299M info
GNLX
Aug 13, 2026, 1:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.75
Real-time Price: $2.20 info
Change: -$0.550 (-20%) info
Market Cap: $104.299M info
GNLX
May 07, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.83
Real-time Price: $2.20 info
Change: -$0.630 (-22%) info
Market Cap: $104.299M info
GNLX
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $2.53
Real-time Price: $2.20 info
Change: -$0.330 (-13%) info
Market Cap: $104.299M info
GNLX
Mar 19, 2026, 5:30 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $2.54
Real-time Price: $2.20 info
Change: -$0.340 (-13%) info
Market Cap: $104.299M info
GNLX
Mar 19, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.54
Real-time Price: $2.20 info
Change: -$0.340 (-13%) info
Market Cap: $104.299M info
GNLX
Mar 19, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.54
Real-time Price: $2.20 info
Change: -$0.340 (-13%) info
Market Cap: $104.299M info
GNLX
Feb 02, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.73
Real-time Price: $2.20 info
Change: -$0.530 (-19%) info
Market Cap: $104.299M info
GNLX
Jan 08, 2026, 5:09 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.75
Real-time Price: $2.20 info
Change: -$0.550 (-20%) info
Market Cap: $104.299M info
GNLX
Jan 08, 2026, 5:05 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.75
Real-time Price: $2.20 info
Change: -$0.550 (-20%) info
Market Cap: $104.299M info
GNLX
Jan 07, 2026, 4:48 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.06
Real-time Price: $2.20 info
Change: -$0.860 (-28%) info
Market Cap: $104.299M info
GNLX
Jan 05, 2026, 8:16 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.60
Real-time Price: $2.20 info
Change: -$2.40 (-52%) info
Market Cap: $104.299M info
GNLX
Jan 02, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.55
Real-time Price: $2.20 info
Change: -$2.35 (-52%) info
Market Cap: $104.299M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets